Nadina has over 15 years experience in drug development within industry and academia and her career has progressed from basic cancer research across the whole spectrum of translational research to pre- and clinical studies and post-registration activities. Following the completion of her PhD in cancer pharmacology (University of Bradford, UK) and postdoctoral fellowship in molecular aspects of cancer angiogenesis (University of Leeds, UK), she worked for Novartis and AstraZeneca on various drug development projects (lead optimization to Phase III), moving from technical to strategic and leadership roles. She returned to the University of Leeds where she helped set up a multimillion translational research initiative and managed the Leeds Cancer Research UK Centre. In 2012 she returned to industry but this time to a SME (uniQure) where she led a number of early development gene therapy programmes (pre-clinical to Phase I/II) working in niche/ rare indications. Nadina also holds a Master in Public Health (University of Manchester, UK) and a mini MBA (Kauffman Fellows Academy). Since 2009, she is serving as an Expert Reviewer for the European Commission’s Research and Innovation programme (Framework Programme 7 and Horizon 2020) and since 2010 she is a National Representative for the European Association for Predictive, Preventive and Personalised Medicine. In March 2015 she joined SMS-oncology as Director Consultancy.